Is Walgreen the Clear-Cut Pharmacy Favorite if It Acquires Alliance Boots?

Walgreen is reportedly preparing to acquire the remaining 55% stake in Alliance Boots, but what does this mean for you?

May 26, 2014 at 9:17AM

Walgreen (NASDAQ:WBA) is reportedly considering an acquisition of the remaining 55% stake of Alliance Boots that it doesn't already own. Walgreen purchased a 45% stake in the company back in 2012 for $6.7 billion and now has a six-month option to acquire the rest starting in 2015. Therefore, assuming this deal eventually occurs, as expected, how will it affect Walgreen's investment value, particularly against the likes of Rite Aid (NYSE:RAD) and CVS Caremark (NYSE:CVS)?

Why buy Alliance Boots?
Alliance Boots operates the UK's largest chain of pharmacies; therefore in expanding globally, investors can identify that an acquisition gives Walgreen room for European expansion. Moreover, Alliance Boots is a large company...and fast-growing.

For fiscal 2014, revenue grew 4.3% to $32 billion, and net profit increased 31% to $1.3 billion in part due to cost-synergies associated with the Walgreen ownership. While adding a business of this size would most certainly create further synergies and perhaps boost the investment value of Walgreen, the real value lies in tax rates.

Industrywide margin improvements despite high taxes
The top corporate tax rate in the U.S. sits at 35%, in which all three of the largest pharmacies, Walgreen, CVS, and Rite Aid, are forced to pay. The pharmacy sector in general has historically had among the lowest operating margins of any sector in the market, joined with grocery. However, the patent cliff  -- $130 billion of brand drugs lose patent protection between 2011 and 2016 -- has driven margins higher over the last few years.

The reason generics generate higher margins is because the drugs are bought in bulk, saving on logistical costs, and have more flexibility for mark-ups. Specifically, Rite Aid has staged a return to profitability since 2012, including an accumulative operating margin increase of more than 5%, which has consequently driven stock gains of more than 600% since late-2012. Up until recently, Rite Aid had zero revenue growth, and its stock gains were all tied to margins. However, in 2014, its stock gains of 50% have been largely a result of new-found growth, including an April same store sales increase of nearly 5%, putting it on par with CVS and Walgreen.

Nonetheless, these three enormous pharmacies create more than $220 billion in combined annual revenue, are all expected to generate year-over-year growth in the next two years, and pay the highest possible tax rate in the U.S. Currently, Rite Aid's operating margin is about half of its two larger peers; and as more generics are introduced to the market, many believe it has the most to gain as it continues to see bottom-line improvements.

Boots gives Walgreen a clear advantage
However, if Walgreen acquires Alliance Boots for a remaining $9.5 billion, $16.2 billion total, it'll then have the upper hand from an investment perspective. Already, CVS' valuation has come into question, and it has an industry-best 6.5% operating margin, leaving the least amount of room for operational upside. Specifically, CVS's pharmacy gross margin increased just 40 basis points in its last quarter, growing far slower than retail, showing that profits are getting tighter in comparison to the last two years.

Albeit, Rite Aid and Walgreen are largely considered the two companies with the most upside moving forward, and the Boots acquisition may sway sentiment in the latter's favor. If Walgreen acquires the remaining stake in Boots, it'll almost certainly relocate to the U.K., ending a 113-year history as a U.S. company, based in Chicago. Investors might wonder why, and the answer is to capitalize on the U.K.'s 21% tax rate, a luxury that no other pharmacy will have.

Final thoughts
To put this in perspective, Walgreen is more than twice the size of Boots in revenue and profits and is by operational standards a more efficient company. Yet, it's estimated that by being in the U.K., Boots profits more than $165 million a year versus being in the U.S., or about a 12% boost to its bottom line.

If we look at Walgreen, think of what a 12% boost to its bottom line could do for the stock along with acquiring another $1.3 billion in profits and $32 billion in revenue from Boots. Essentially, this combination could add substantial value to Walgreen's stock and make it the clear stock to own in the pharmacy space.

Your credit card may soon be completely worthless
The plastic in your wallet is about to go the way of the typewriter, the VCR, and the 8-track tape player. When it does, a handful of investors could stand to get very rich. You can join them -- but you must act now. An eye-opening new presentation reveals the full story on why your credit card is about to be worthless -- and highlights one little-known company sitting at the epicenter of an earth-shaking movement that could hand early investors the kind of profits we haven't seen since the dot-com days. Click here to watch this stunning video.


Brian Nichols owns shares of Rite Aid. The Motley Fool recommends CVS Caremark. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information